WARREN, R.; REICH, K.; SIMPSON, E.; LANGLEY, R.; COSTANZO, A. .; SAEKI, H.; ALMGREN, P.; VACKO, E.; CARLSSON, A.; GOODERHAM, M.; DELEURAN, M.; SILVESTRE, J. F.; WEIDINGER, S.; BLAUVELT, A. 3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s142, 2023. DOI: 10.25251/skin.7.supp.142. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/2028. Acesso em: 3 jul. 2024.